Fintech PR
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
- Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate
- Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million)
LONDON, Feb. 1, 2024 /PRNewswire/ — NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three new investors – NEVA SGR (the venture capital arm of Intesa Sanpaolo banking group), LIFTT (the venture capital focused on deep-tech chaired by Stefano Buono) and Simon Fiduciaria (the fiduciary company of Ersel Group). This extension brings the total raised in Series B financing to £31.1m (approx. USD $39.5m).
NeoPhore is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (‘MMR’) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore’s first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.
2023 was a great year of progress for NeoPhore. At AACR-NCI-EORTC in Boston in October, the first disclosure of lead compound NP1867 was presented. This demonstrated that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.
The additional Series B funding will be used to progress NeoPhore’s lead oral program, through early pre-clinical development.
Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: “NeoPhore has made excellent progress throughout 2023. With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.”
Dr Robert James, Chairman of NeoPhore, said: “Over the past years NeoPhore has made tremendous strides in showing that it is possible to target the MMR pathway with small molecule inhibitors. The recent data the Company has generated and presented at an international conference leads us to believe that NeoPhore’s approach may be profoundly important. We are pleased to welcome three new Italian-based investors to our syndicate as well as further funding from existing investors. Their commitment reflects the potential value of NeoPhore’s approach that exploits the dynamics of cancer neoantigen evolution, through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies. We are very excited about the next stage in the life of the Company.”
About NeoPhore Ltd
NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. For more information, please visit www.neophore.com
About NEVA SGR
Neva SGR, venture capital arm of the Intesa Sanpaolo Group and wholly owned by the Intesa Sanpaolo Innovation Center, plans and manages investment funds for professional investors interested in seizing diversification and high-yield opportunities offered by Venture Capital investments. Neva SGR can count on Intesa Sanpaolo Innovation Center’s and Intesa Sanpaolo Group’s strength, financial resources, know-how and network of relationships, a unique source of value on the market. Neva SGR can watch trends and markets from a privileged position and takes action with the strength and the responsibility of Italy’s leading banking group. Intesa Sanpaolo Innovation Center has invested in Neva First, the investment fund designed for excellent, high-tech, high-innovation start-ups, which take advantage of trends with exponential growth potential.
To learn more visit www.nevasgr.com
About LIFTT
Chaired by the scientist and entrepreneur Stefano Buono, LIFTT’s aim is to encourage technology development and transfer from University to Industry, but also to clear the way from a simple business idea to the creation of an innovative product, offering a dynamic and modern vision of venture capital as applied to Technology Transfer. To date, LIFTThas raised EUR 103,5 million and has completed 47 investments, from a pipeline of +3000 companies, operating in all market sectors, with a particular focus on Deep Tech. www.liftt.com Head of Communications & Investor relations: [email protected]
About Simon Fiduciaria
Simon Fiduciaria is the fiduciary and trust company of Ersel Group which since 1936 has been a specialist in wealth management and a unique company in Italy for its absolute independence, professionalism, quality of service, and direct and personal relationship with the client.
Founded in 1986, Simon Fiduciaria stands out for its independence as well as its operational and professional qualities, to fully meet the needs of its customers. As a reference point for the Italian fiduciary market, with over 7 billion administered assets, Simon Fiduciaria has developed, alongside fiduciary and trust heading services, an innovative service dedicated to large private and institutional assets, with independent and analytical monitoring that offers an aggregated view of allocation, performance, and risks, and highlights potential areas for improvement.
About Sixth Element Capital LLP and the CRT Pioneer Fund
Sixth Element Capital LLP (6EC) is a UK based fund manager, which manages the CRT Pioneer Fund. 6EC’s experienced partners focus on creative and collaborative novel financing solutions designed to fund and manage innovative science in order to bring new therapeutic products and technologies to market, creating long term value and benefit to stakeholders. The CRT Pioneer Fund is a specialist oncology investment fund established by 6EC in 2012. The £70 million fund is dedicated to investments in oncology development programmes in Europe. The fund was established to bridge the investment gap between cancer drug discovery and early clinical development.
For more information, please see www.sixthelementcapital.com
About Claris Ventures
Claris Ventures is a biotech-focused venture capital firm based in Turin (Italy). Its first fund under management, Claris Biotech I, was launched in 2020 to finance high potential biopharma companies arisen from the Italian R&D ecosystem – both local and international. We identify and support innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. We aim at the highest impact possible on highly unmet patients’ needs, building value around strong science. Our pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy.
http://www.clarisventures.com/
About 3B Future Health Fund II
3B Future Health Fund II S.C.A. SICAV-RAIF is a Luxembourg based investment fund investing in oncology and rare disease therapeutics in Europe and the United States. The firm’s goal is to identify innovative and promising companies that are developing First-in-Class therapeutics for indications with high unmet patient needs and provide them with the financial resources and strategic guidance they need to succeed. The fund targets companies with strong management teams, a solid scientific foundation, and a clear path to regulatory approval and commercialization. We seek to invest in early-stage companies with promising preclinical data. Additionally, the fund’s investment team has extensive experience in the pharma industry, a track record of success in drug development and identifying high-potential investments. 3B is committed to creating value for its investors while also making a positive impact on the lives of patients. For more information please see www.3bfuturehealth.com
About Astellas Venture Management LLC
Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to reinforcing Astellas Pharma Inc. (Astellas) to accomplish the strategic goals. The venture capital activity of AVM is designated since 2005. Astellas, the ultimate parent company of AVM, headquartered in Tokyo is actively engaged in business as an R&D-driven global pharmaceutical company with the business philosophy to “Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products”. Through strategic investments in private early-stage companies, the funds aim to mutual-interact with Astellas, leading to partnering/collaboration in the future. AVM will be able to provide portfolio companies with invaluable R&D advice and assistance.
About 2Invest
2Invest AG (2Invest) is an investment company listed on Frankfurt market formed in 2020 from the restructuring of businesses of 4basebio AG. Our investment objective is primarily but not exclusively to identify and support emerging companies with both strong management teams and ground-breaking technologies in the biotechnology, life sciences and IT sectors. Our ambition is to enable those companies to reach new and meaningful value inflexion points.
View original content:https://www.prnewswire.co.uk/news-releases/neophore-raises-an-additional-9-6m-usd-12-2m-series-b-financing-extension-to-further-progress-drug-discovery-pipeline-302049681.html
BALA CYNWYD, Pa., Nov. 26, 2024 /PRNewswire/ — Radius Global Infrastructure, Inc. has announced the appointment of Benjamin Lowe as Chief Financial Officer, effective December 2, 2024. The announcement was made by Scott G. Bruce, Chief Executive Officer of Radius Global Infrastructure, Inc.
In his new role, Mr. Lowe will lead the company’s financial operations, including treasury, accounting, financial planning and analysis, and tax functions. He succeeds Glenn J. Breisinger, who will retire and step down as Chief Financial Officer of Radius. Mr. Breisinger will remain with the company during the transition through the first quarter of 2025. Mr. Lowe will report directly to Mr. Bruce and collaborate closely with him and the senior management team on critical strategic initiatives. He will be based at the company’s headquarters in Bala Cynwyd, Pennsylvania.
“Ben has proven leadership and expertise in all facets of finance and corporate management and brings a wealth of financial, transactional and operational experience with many forms of digital infrastructure, which will be invaluable to Radius,” Mr. Bruce said. “We are pleased to welcome him to the team and look forward to his contributions as a key member of our senior leadership group.”
Mr. Lowe joins Radius Global Infrastructure, Inc. from Crown Castle, where he built a successful career, holding the position of Senior Vice President, Corporate Finance and Treasurer. In addition to his financial leadership roles, he held an operational position as Vice President of Leasing and Real Estate Operations. Mr. Lowe holds a Bachelor of Arts in Economics and a minor in Political Science from Lenoir-Rhyne University.
About Radius Global Infrastructure, Inc.
Radius is a leading acquirer of real property interests underlying wireless telecommunications cell sites and other digital infrastructure assets. With over 11,000 lease streams spanning 23 countries, it is one of the largest international real property acquirers globally. Radius is a portfolio company of EQT Active Core Infrastructure SCSp and the Public Sector Pension Investment Board. More information about Radius Global Infrastructure, Inc. is available at https://www.radiusglobal.com.
Media Inquiries:
Marlyn García
Vice President, Marketing
Email: [email protected]
Phone: (619) 359-3925
Logo – https://mma.prnewswire.com/media/2567082/Radius_Global_Infrastructure_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/radius-global-infrastructure-inc-appoints-benjamin-lowe-as-chief-financial-officer-302316080.html
Fintech PR
Miami International Holdings Congratulates Markets Media Women in Finance Award Recipients Barbara Comly and Kelli Annequin
MIAMI and PRINCETON, N.J., Nov. 26, 2024 /PRNewswire/ — Miami International Holdings, Inc. (MIH), a technology-driven leader in building and operating regulated financial markets across multiple asset classes, today announced that Barbara Comly, Executive Vice President, General Counsel and Corporate Secretary, and Kelli Annequin, Senior Vice President and Chief Marketing Officer, were recognized at Markets Media Group’s 10th-annual U.S. Women in Finance (WIF) Awards.
Ms. Comly received the Excellence in Regulation award, an acknowledgement of her deep expertise in exchange regulation and corporate finance, which have proved invaluable as MIH has expanded the number of exchanges it operates through both regulatory approvals and multiple acquisitions.
“I am honored to be selected by Markets Media for the Excellence in Regulation award, providing me an opportunity to represent women pursuing their passions and making an impact in the financial industry,” said Ms. Comly. “MIH has a strong history of providing growth opportunities for all employees and I am fortunate to represent a company with core values focused on advancement for everyone.”
Ms. Annequin won the Excellence in Marketing and Communications award for directing the expansion of marketing and advertising activities for MIAX®. Since joining MIH, she has led a number of campaigns including programs focusing on the launch of MIAX Sapphire™, MIH’s newest options exchange, and the renaming and rebranding of Minneapolis Grain Exchange, LLC (MGEX) to MIAX Futures Exchange, LLC (MIAX Futures™).
“I want to thank Markets Media for highlighting the achievements of women in our industry,” said Ms. Annequin. “It’s an honor to be recognized among such an esteemed group of professionals. MIH is a leader in providing opportunities for its employees and I am grateful to be part of a management team that embraces these values which contribute to our dynamic and inclusive culture.”
“We are incredibly proud to celebrate this achievement with Barbara and Kelli as they pave the way for future generations of women in our industry,” said Thomas P. Gallagher, Chairman and Chief Executive Officer of MIH. “Barbara has been with MIH since its inception and her legal and regulatory expertise has been critical to the success of all our exchanges, as well as the growth of the company. We are also fortunate to have Kelli on our team, as her strategic insights and marketing acumen are significantly raising the profile of MIAX in our industry.”
Since 2015, Markets Media Group’s WIF Awards recognize and celebrate the most talented and accomplished women in multiple categories across finance. WIF nominees are put forth by readers of Markets Media and Traders Magazine, and winners are determined by the editorial staffs of the two U.S. editorial platforms, in conjunction with the WIF Advisory Board.
About MIAX
MIAX’s parent holding company, Miami International Holdings, Inc., owns Miami International Securities Exchange, LLC (MIAX®), MIAX PEARL, LLC (MIAX Pearl®), MIAX Emerald, LLC (MIAX Emerald®), MIAX Sapphire LLC (MIAX Sapphire™), MIAX Futures Exchange, LLC (MIAX Futures™), MIAX Derivatives Exchange (MIAXdx™), The Bermuda Stock Exchange (BSX) and Dorman Trading, LLC (Dorman Trading).
MIAX, MIAX Pearl, MIAX Emerald and MIAX Sapphire are national securities exchanges registered with the Securities and Exchange Commission that are enabled by MIAX’s in-house built, proprietary technology. MIAX offers trading of options on all four exchanges as well as cash equities through MIAX Pearl Equities™. The MIAX trading platform was built to meet the high-performance quoting demands of the U.S. options trading industry and is differentiated by throughput, latency, reliability and wire-order determinism.
MIAX Futures is a registered exchange with the Commodity Futures Trading Commission (CFTC) and offers trading in a variety of products including Hard Red Spring Wheat Futures. MIAX Futures is a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO) under the CFTC, providing DCM and DCO services in an array of asset classes.
MIAXdx is a CFTC regulated exchange and clearinghouse and is registered as a Designated Contract Market (DCM), Derivatives Clearing Organization (DCO), and Swap Execution Facility (SEF) with the CFTC.
BSX is a fully electronic, vertically integrated international securities market headquartered in Bermuda and organized in 1971. BSX specializes in the listing and trading of capital market instruments such as equities, debt issues, funds, hedge funds, derivative warrants, and insurance linked securities.
Dorman Trading is a full-service Futures Commission Merchant registered with the CFTC.
MIAX’s executive offices and National Operations Center are located in Princeton, N.J., with additional U.S. offices located in Chicago, IL and Miami, FL. MIAX Futures offices are located in Minneapolis, MN. MIAXdx offices are located in Princeton, N.J. BSX offices are located in Hamilton, Bermuda. Dorman Trading offices are located in Chicago, IL.
To learn more about MIAX visit www.miaxglobal.com.
To learn more about MIAX Futures visit www.miaxglobal.com/miax-futures.
To learn more about MIAXdx visit www.miaxdx.com.
To learn more about BSX visit www.bsx.com.
To learn more about Dorman Trading visit www.dormantrading.com.
Disclaimer and Cautionary Note Regarding Forward-Looking Statements
The press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities of Miami International Holdings, Inc. (together with its subsidiaries, the Company), and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer; solicitation or sale would be unlawful. This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.
All third-party trademarks (including logos and icons) referenced by the Company remain the property of their respective owners. Unless specifically identified as such, the Company’s use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between the owners of these trademarks and the Company. Any references by the Company to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
Media Contact:
Andy Nybo, SVP, Chief Communications Officer
(609) 955-2091
[email protected]
Logo – https://mma.prnewswire.com/media/1396492/MIAX_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/miami-international-holdings-congratulates-markets-media-women-in-finance-award-recipients-barbara-comly-and-kelli-annequin-302316206.html
The contract signed with Sigma Lifesciences consolidates the presence of the Italian company in North America, where its subsidiary PharmaNutra USA Corp. is already active
PISA, Italy, Nov. 26, 2024 /PRNewswire/ — The Board of Directors of PharmaNutra S.p.A. (MTA; Ticker PHN), a company specialized in nutritional supplements based on minerals and medical devices for muscles and joints, announces the closing of a new significant international distribution agreement.
The contract has been signed with the Canadian pharmaceutical company Sigma Lifesciences, which is active in the production and distribution of health products, for the sale of four products in Canada, adding to the over 80 countries where the company founded in 2003 by Andrea and Roberto Lacorte is already present.
Specifically, Sigma Lifesciences will handle the distribution in Canada of SiderAL® Forte, SiderAL® Folic, and SiderAL® Drops, dietary supplements based on Sucrosomial® Iron, developed using the patented Sucrosomial® Technology, an innovative delivery system that protects the molecules of micronutrients like iron, enhancing absorption and improving tolerability.
As part of the marketing plan for SiderAL® products, scheduled for the second quarter of 2025 with the launch of SiderAL® Forte, SiderAL® Folic, and SiderAL® Drops,a training session for the Sigma Lifesciences team was held last week in Toronto, conducted by the Scientific and Commercial Management of PharmaNutra. During this event, one Focus Groups took place with more than thirty Canadian pharmacists and doctors from various therapeutic areas – Gynecology, Hematology, Internal Medicine and Oncology – aimed at developing the knowledge of Sucrosomial® Technology and understanding the specific needs of the local market.
In addition to the three SiderAL® products – leaders in the market for oral iron products in many countries – Ultramag®, a dietary supplement based on Sucrosomial® Magnesium, will also be part of Sigma Lifesciences’ product portfolio.
Either Ultramag® and the SiderAL® products – Forte, Folic, and Drops – have received official registration from Health Canada for commercialization in the country.
Carlo Volpi, COO of PharmaNutra S.p.A., states: “The agreement with Sigma Lifesciences is very important from several perspectives, starting with the fact that with Canada we complete our presence in North America. We are talking about a market with considerable potential, so we are truly confident about the impact that our products, based on innovative patented technologies, can have in the region. The contribution of our partner, Sigma Lifesciences, a renowned and relevant player, will play a crucial role in the development of our business in Canada“.
CONTACT:
Investor Relations Pharmanutra , 050 7846500, [email protected]
Emanuel Richelmy, Pharmanutra, +39 391 7310645, [email protected]
Cristina Tronconi, +39 346 0477901, [email protected]
Matteo Russo, +39 347 9834881, [email protected]
Logo – https://mma.prnewswire.com/media/2396011/PharmaNutra_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/pharmanutra-spa-distribution-agreement-for-sideral-products-signed-in-canada-302315295.html
-
Fintech6 days agoFintech Pulse: Industry Updates, Innovations, and Strategic Moves
-
Fintech5 days agoFintech Pulse: Daily Industry Brief – A Dive into Today’s Emerging Trends and Innovations
-
Fintech PR5 days agoTAILG Represents the Industry at COP29, Advancing South-South Cooperation with Low-Carbon Solutions
-
Fintech PR6 days agoROLLER Releases 2025 Attractions Industry Benchmark Report, Unveiling Key Trends and Revenue Strategies
-
Fintech7 days agoFintech Pulse: Milestones, Partnerships, and Transformations in Fintech
-
Fintech PR4 days agoAlkira Ranked 25th Fastest-Growing Company in North America and 6th in the Bay Area on the 2024 Deloitte Technology Fast 500™
-
Fintech PR6 days agoThe CfC St. Moritz Announces New Speakers from BlackRock, Binance, Bpifrance, Temasek, PayPal, and More for Upcoming 2025 Conference
-
Fintech PR4 days agoCorinex Ranked Number 331 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™